Moreover, the combination of ND-MPLA/CpG with OVA increased 8-fold antigen-specific CD8+ T cell response pivotally, promoting the regression of B16F10-OVA melanoma compared with free adjuvant [120]. Here, CD8A is linked to melanoma.